ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,083.57
0.36%
Dow Jones
44,747.63
-0.28%
US Dollar vs MXN
20.447
-0.64%
Brent Oil
74.125
-0.61%
Bitcoin
96,501.20
-0.12%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. XOMA Royalty Corporation (XOMA)

  7. XOMA Royalty Corporation (XOMA) Noticias

XOMA

XOMA Royalty (XOMA)

XOMA Royalty Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XOMA
FechaHoraFuenteTítuloSímboloCompañía
04/02/202506:30GlobeNewswire Inc.XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:XOMAXOMA Royalty Corporation
19/12/202406:30GlobeNewswire Inc.XOMA Royalty Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Royalty Corporation
02/12/202406:30GlobeNewswire Inc.XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its PortfolioNASDAQ:XOMAXOMA Royalty Corporation
07/11/202406:30GlobeNewswire Inc.XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAXOMA Royalty Corporation
22/10/202407:00GlobeNewswire Inc.XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist BioscienceNASDAQ:XOMAXOMA Royalty Corporation
23/09/202405:30GlobeNewswire Inc.Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)NASDAQ:XOMAXOMA Royalty Corporation
04/09/202406:30GlobeNewswire Inc.XOMA Royalty to Present at Upcoming Investor Conferences in SeptemberNASDAQ:XOMAXOMA Royalty Corporation
13/08/202406:30GlobeNewswire Inc.XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAXOMA Royalty Corporation
20/06/202406:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Royalty Corporation
12/06/202406:30GlobeNewswire Inc.XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review VoucherNASDAQ:XOMAXOMA Royalty Corporation
14/05/202406:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQNASDAQ:XOMAXOMA Royalty Corporation
09/05/202406:30GlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAXOMA Royalty Corporation
30/04/202406:30GlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAXOMA Royalty Corporation
25/04/202406:30GlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Royalty Corporation
24/04/202408:00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:XOMAXOMA Royalty Corporation
03/04/202408:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAXOMA Royalty Corporation
19/03/202415:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAXOMA Royalty Corporation
08/03/202406:30GlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Royalty Corporation
28/02/202406:30GlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAXOMA Royalty Corporation
16/02/202407:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAXOMA Royalty Corporation
18/01/202407:30GlobeNewswire Inc.XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionNASDAQ:XOMAXOMA Royalty Corporation
11/01/202415:50Dow Jones NewsXoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolNASDAQ:XOMAXOMA Royalty Corporation
11/01/202415:05GlobeNewswire Inc.FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxNASDAQ:XOMAXOMA Royalty Corporation
08/01/202406:30GlobeNewswire Inc.XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsNASDAQ:XOMAXOMA Royalty Corporation
02/01/202406:30GlobeNewswire Inc.XOMA Announces Stock Repurchase Program of up to $50 MillionNASDAQ:XOMAXOMA Royalty Corporation
19/12/202306:30GlobeNewswire Inc.XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesNASDAQ:XOMAXOMA Royalty Corporation
07/11/202306:30GlobeNewswire Inc.XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Royalty Corporation
31/10/202306:30GlobeNewswire Inc.XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Royalty Corporation
06/09/202306:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:XOMAXOMA Royalty Corporation
08/08/202306:30GlobeNewswire Inc.XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyNASDAQ:XOMAXOMA Royalty Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMA

Su Consulta Reciente

LSE
IGP
Intercede
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios